CJC-1295 (with DAC)

Long-acting GHRH analogue that raises baseline GH and IGF-1.

Typical dose range: 1–2 mg

Frequency: Weekly

Route: Subcutaneous

Half-life: ~6–8 days

Evidence level: Phase 1

Overview

DAC technology lets the molecule bind albumin for sustained GH release. Less popular now that pulsatile GHRP+GHRH stacks are favoured.